Effect of mild and moderate hepatic impa
β
Alfred E. Corey; Jeffrey R. Agnew; Eileen C. King; Nikhil J. Parekh; James H. Po
π
Article
π
2004
π
John Wiley and Sons
π
English
β 109 KB
Azimilide dihydrochloride (75-125 mg/day) is currently being developed for use in prolonging the time to recurrence of atrial fibrillation/flutter and for reducing the frequency of shocks in patients with an implantable cardioverting defibrillator. This study investigated the influence of mild and m